CPT® Code 95857

Cholinesterase inhibitor challenge test for myasthenia gravis, identified by CPT® Code 95857, is a diagnostic procedure utilized to assess the presence of myasthenia gravis, an autoimmune disorder characterized by the production of antibodies that target acetylcholine nicotinic post-synaptic receptors at the myoneural junction. This condition leads to a progressive decline in muscle strength during activity, with a notable recovery of strength following rest periods. Myasthenia gravis can manifest in a generalized form or may be localized, particularly affecting bulbar muscles, which can result in symptoms such as facial muscle weakness, ptosis (drooping of the eyelids), double or blurred vision, difficulties in swallowing, and disturbances in speech. The cholinesterase inhibitor challenge test involves the intravenous administration of a cholinesterase inhibitor, commonly edrophonium (known by the brand name Tensilon). The primary objective of this test is to evaluate the patient's muscle strength response to the medication. If the initial dose does not yield an improvement in muscle strength, higher doses may be administered incrementally to provoke a positive response. A significant improvement in muscle strength following the administration of the cholinesterase inhibitor indicates a negative result for myasthenia gravis, thereby aiding in the diagnosis and informing subsequent treatment decisions.